Advances in the Selection of Patients with Prostate Cancer for Active Surveillance

Tools for prostate cancer diagnosis have the potential to further improve the identification of men with low-risk disease who can be appropriately managed using active surveillance.
[Nature Reviews Urology]
Liu, J. L., Patel, H. D., Haney, N. M., Epstein, J. I., & Partin, A. W. (2021). Advances in the selection of patients with prostate cancer for active surveillance. Nature Reviews Urology, 1–12. https://doi.org/10.1038/s41585-021-00432-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Researchers characterized circulating tumor cells for expression of immune checkpoint ligands in men with metastatic prostate cancer as a non-invasive biomarker of immune evasion and immunotherapy benefit.
[Biomarker Research]
Zhang, T., Agarwal, A., Almquist, R. G., Runyambo, D., Park, S., Bronson, E., Boominathan, R., Rao, C., Anand, M., Oyekunle, T., Healy, P., McNamara, M. A., Ware, K., Somarelli, J. A., George, D. J., & Armstrong, A. J. (2021). Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research, 9(1), 14. https://doi.org/10.1186/s40364-021-00267-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Treating the Patient and Not Just the Cancer: Therapeutic Burden in Prostate Cancer

Investigators summarize the multiple factors that may contribute to the therapeutic burden of patients with castration-resistant prostate cancer, including the interplay between age, comorbidities, concomitant medications, the use of androgen receptor inhibitors, and financial distress.
[Prostate Cancer and Prostatic Diseases]
Spratt, D. E., Shore, N., Sartor, O., Rathkopf, D., & Olivier, K. (2021). Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer and Prostatic Diseases, 1–15. https://doi.org/10.1038/s41391-021-00328-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Modulating the Unfolded Protein Response with ONC201 to Impact on Radiation Response in Prostate Cancer Cells

Researchers enhanced the acute activation of the unfolded protein response (UPR) using radiation and ONC201, an UPR activator. Treating prostate cancer cells with ONC201 quickly increased the expression of all the key regulators of the UPR and reduced the oxidative phosphorylation, with cell death.
[Scientific Reports]
Amoroso, F., Glass, K., Singh, R., Liberal, F., Steele, R. E., Maguire, S., Tarapore, R., Allen, J. E., Van Schaeybroeck, S., Butterworth, K. T., Prise, K., O’Sullivan, J. M., Jain, S., Waugh, D. J., & Mills, I. G. (2021). Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. Scientific Reports, 11(1), 4252. https://doi.org/10.1038/s41598-021-83215-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

GRPr-Mediated Photothermal and Thermodynamic Dual-Therapy for Prostate Cancer with Synergistic Anti-Apoptosis Mechanism

An in vitro study with the castration resistant prostate cancer cell exhibited a significant photothermal therapeutic effect as well as enhanced thermodynamic therapy via generating free radicals.
[Nanoscale]
Xu, H., Sheng, G., Lu, L., Wang, C., Zhang, Y., Feng, L., Meng, L., Min, P., Zhang, L., Wang, Y., & Han, F. (2021). GRPr-mediated photothermal and thermodynamic dual-therapy for prostate cancer with synergistic anti-apoptosis mechanism. Nanoscale. https://doi.org/10.1039/D0NR07196J Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

EWI-2 Controls Nucleocytoplasmic Shuttling of EGFR Signaling Molecules and miRNA Sorting in Exosomes to Inhibit Prostate Cancer Cell Metastasis

The authors found that EWI-2 localized on both the cell membrane and exosomes regulated the distribution of miR-3934-5p between cells and exosomes.
[Molecular Oncology]
EWI‐2 controls nucleocytoplasmic shuttling of EGFR signaling molecules and miRNA sorting in exosomes to inhibit prostate cancer cell metastasis - Fu - - Molecular Oncology - Wiley Online Library. (n.d.). Retrieved February 19, 2021, from https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12930 Cite
AbstractFull Article
Bookmark

No account yet? Register

0
Share

MAPK4 Promotes Prostate Cancer by Concerted Activation of Androgen Receptor and AKT

Scientists demonstrated that MAPK4 activated androgen receptor (AR) by enhancing GATA2 transcriptional expression and stabilizing GATA2 protein through repression of GATA2 ubiquitination/degradation. MAPK4 expression correlated with AR activation in human castration-resistant prostate cancer.
[Journal of Clinical Investigation]
Shen, T., Wang, W., Zhou, W., Coleman, I., Cai, Q., Dong, B., Ittmann, M. M., Creighton, C. J., Bian, Y., Meng, Y., Rowley, D. R., Nelson, P. S., Moore, D. D., & Yang, F. (2021). MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. The Journal of Clinical Investigation, 131(4). https://doi.org/10.1172/JCI135465 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Patient-Derived Xenografts and Organoids Model Therapy Response in Prostate Cancer

The authors describe an androgen-dependent prostate cancer patient-derived xenograft model from treatment-naïve, soft tissue metastasis.
[Nature Communications]
Karkampouna, S., La Manna, F., Benjak, A., Kiener, M., De Menna, M., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., Vallerga, A., Theurillat, J.-P., De Filippo, M. R., Genitsch, V., Keller, D., Booij, T. H., Stirnimann, C. U., Eng, K., Sboner, A., … Kruithof-de Julio, M. (2021). Patient-derived xenografts and organoids model therapy response in prostate cancer. Nature Communications, 12(1), 1117. https://doi.org/10.1038/s41467-021-21300-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

BRG1 Knockdown Inhibits Proliferation through Multiple Cellular Pathways in Prostate Cancer

Investigators probed the functions of BRG1 on a background of prostate cancer to investigate how BRG1 controls gene expression programs and cancer cell behavior.
[Clinical Epigenetics]
Giles, K. A., Gould, C. M., Achinger-Kawecka, J., Page, S. G., Kafer, G. R., Rogers, S., Luu, P.-L., Cesare, A. J., Clark, S. J., & Taberlay, P. C. (2021). BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer. Clinical Epigenetics, 13(1), 37. https://doi.org/10.1186/s13148-021-01023-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Ultimovacs ASA announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform.
[Ultimovacs ASA]
Press Release
Bookmark

No account yet? Register

0
Share

Regulation of Anti-Tumorigenic Pathways by the Combinatory Treatment of Calcitriol and TGF-β in PC-3 and DU145 Cells

Researchers in vitro analyzed the combinatory effects of calcitriol and transforming growth factors beta (TGF-β) on cell growth and apoptosis using PC-3 and DU145 human prostate cancer cell lines.
[Journal of Steroid Biochemistry and Molecular Biology]
García-Olivares, M., Romero-Córdoba, S., Ortíz-Sánchez, E., García-Becerra, R., Segovia-Mendoza, M., Rangel-Escareño, C., Halhali, A., Larrea, F., & Barrera, D. (2021). Regulation of anti-tumorigenic pathways by the combinatory treatment of calcitriol and TGF-β in PC-3 and DU145 cells. The Journal of Steroid Biochemistry and Molecular Biology, 105831. https://doi.org/10.1016/j.jsbmb.2021.105831 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share